The latest genitourinary oncology news
AUA 2024: TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer
New data from Phase 2b SunRISe-1 study show rapid complete response (CR) achievement with 98% achieving a…